Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clyde Bailey

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Bioinformatics (Oxford, England)|February 16, 2002
CGO: utilizing and integrating gene expression microarray data in clinical research and data managementKlaus Bumm, Mingzhong Zheng, Clyde Bailey, et al.
Cancer|July 2, 2011
Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxisElias J Anaissie, Elizabeth A Coleman, Julia A Goodwin, et al.
Clinical Case Reports|April 4, 2015
Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocolsZeba N Singh, Yogesh Jethava, Ginell R Post, et al.
American Journal of Hematology|August 7, 2024
Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myelomaSamer Al Hadidi, Obada Ababneh, Carolina Schinke, et al.
Haematologica|May 30, 2013
Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myelomaXenofon Papanikolaou, Jackie Szymonifka, Adam Rosenthal, et al.
Blood Advances|July 1, 2025
Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imagingCarolina Schinke, Leo Rasche, Cody Ashby, et al.
Blood Advances|January 9, 2025
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myelomaSamer Al Hadidi, Obada Ababneh, Carolina Schinke, et al.
Blood Cancer Journal|August 11, 2019
An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q SyndromeJeffrey R Sawyer, Erming Tian, Brian A Walker, et al.
Haematologica|May 30, 2015
Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)Rashid Khan, Madhav Dhodapkar, Adam Rosenthal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2012
Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1Christoph J Heuck, Jackie Szymonifka, Emily Hansen, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Bioinformatics (Oxford, England)|February 16, 2002
CGO: utilizing and integrating gene expression microarray data in clinical research and data managementKlaus Bumm, Mingzhong Zheng, Clyde Bailey, et al.
Cancer|July 2, 2011
Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxisElias J Anaissie, Elizabeth A Coleman, Julia A Goodwin, et al.
Clinical Case Reports|April 4, 2015
Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocolsZeba N Singh, Yogesh Jethava, Ginell R Post, et al.
American Journal of Hematology|August 7, 2024
Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myelomaSamer Al Hadidi, Obada Ababneh, Carolina Schinke, et al.
Haematologica|May 30, 2013
Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myelomaXenofon Papanikolaou, Jackie Szymonifka, Adam Rosenthal, et al.
Blood Advances|July 1, 2025
Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imagingCarolina Schinke, Leo Rasche, Cody Ashby, et al.
Blood Advances|January 9, 2025
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myelomaSamer Al Hadidi, Obada Ababneh, Carolina Schinke, et al.
Blood Cancer Journal|August 11, 2019
An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q SyndromeJeffrey R Sawyer, Erming Tian, Brian A Walker, et al.
Haematologica|May 30, 2015
Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)Rashid Khan, Madhav Dhodapkar, Adam Rosenthal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2012
Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1Christoph J Heuck, Jackie Szymonifka, Emily Hansen, et al.
Pageof 3